Limitations of parallel trade with pharmaceuticals in the practice of the European Commission, ECJ and the Bulgarian Commission for Protection of Competition

The purpose of the article is to outline the key aspects of the limitations of parallel trade with pharmaceuticals and to review the most significant decisions of the ECJ dedicated to this topic, i.e. decisions under the joined cases C-2/01 P и C-3/01 (Bayer/Adalat); case C-277/87 (Sandoz); joined cases C 501/06 P, C-513/06 P, C-515/06 P и C 519/06 P (GSK, Spain); joined cases from C 468/06 to C 478/06 (GSK, Greece) and case T 321/05 (AstraZeneca).